Zogenix Announces Conference Call And Webcast To Present Fourth Quarter And Full Year 2012 Financial Results

SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced it will release financial results for the fourth quarter and full year ended December 31, 2012, before the market opens on Friday, March 15, 2013, and will hold a conference call on this day at 8:30 a.m. ET (5:30 a.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial [phone] (U.S.) or [phone] (International); participant passcode: 73489853.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President and Chief Operating Officer Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning March 15, 2013 at 10:30 a.m. ET (7:30 a.m. PT) until March 22, 2013, by dialing [phone] (U.S.) or [phone] (International); passcode: 78479681. A replay of the webcast will also be accessible on the Investor Relations website for one month, through April 15, 2013.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER. Zogenix's second investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia; an investigational new drug application was submitted to the FDA in May 2012. For additional information, please visit www.zogenix.com .

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [e-mail]
         
         MEDIA:
         Caitlin Cox | The Ruth Group
         646.536.7033 | [e-mail]